Scale AI, the data-labeling company at the center of June 2025's most consequential AI deal, spent the following year answering an unusual question: what happens to a company that sells half its economics, loses its founder to its largest investor, and keeps operating? The documented answer through early 2026 — a repositioned business, concentrated on government, defense, and agent evaluation, with a valuation set by Meta's $14.3 billion for 49 percent at a reported $29 billion, per Reuters. This is an evidence-bounded review; Scale is private and discloses nothing audited, and nothing here is investment advice.
What did the company lose, on the record?
Three documented losses. The founder: Alexandr Wang departed to lead Meta's Superintelligence Labs, taking senior leadership with him. The customers: Google — reported as Scale's largest customer at the time — cut its relationship after the Meta investment, and other consumer-internet labs followed, on the documented logic that Scale's new part-owner was their competitor. And the neutrality: Scale's core business had been selling labeled training data to every frontier lab at once; the Meta stake converted a neutral supplier into a conflicted one, an asset-forfeiture the deal's architects priced in. What the company did not lose: the Meta contract itself — reported at hundreds of millions annually — the cash from the stake, and the underlying delivery operation, thousands of contractors across the labeling workforce.
What did the pivot actually consist of?
The documented repositioning runs on three legs. Defense and government: Scale's existing public-sector unit, which had held contracts including U.S. Department of Defense work through the CCAS vehicle since 2022, became the growth center — expanded through 2025 with additional federal contracts reported, including work tied to the Department of Government Efficiency's data ambitions per press coverage. Agent evaluation: Scale positioned its labeling operations and expert networks as the evaluation layer for AI agents — testing model behavior for labs and enterprises — a market the 2025 agent wave created and that plays to the company's remaining strength. And international sovereign AI programs: data and evaluation contracts with governments building national AI capacity, a category that grew through 2025. What the record does not show: revenue by segment, total revenue post-deal, or retention on the non-consumer business — the company publishes none of it.
How should the $29 billion valuation be read?
As Meta's price for strategy, not a market mark. The stake delivered Wang and a senior team, plus nearly half the economics of a strategically positioned data company, to a buyer for whom the amount was a fraction of quarterly AI capex. For other shareholders — employees with options and earlier investors — the mark matters only at the next priced event, and the documented signals point both ways: the company reportedly explored a tender that would have valued it above the Meta mark, while the lost customer concentration argues the consumer-era revenue base shrank materially. The honest reading: the $29 billion is a documented transaction, not a documented valuation of the current business.
What is the competitive position in what remains?
The labeling market commoditized from below — synthetic data and model-assisted labeling cut prices for basic work, and the frontier labs internalized much of their data operations. What stayed valuable is hard for competitors: expert networks — PhDs, doctors, lawyers, military specialists — supplying high-difficulty human data, and government relationships with clearance and contracting vehicles that take years to build. In both, Scale's documented position is strong, and the competition — Surge, Turing, Invisible, and the labs' in-house teams — is real. The evaluation market additionally pits Scale against the labs' own publishing of benchmarks, a structural tension: the referee is also a player.
What would change the analysis?
Disclosure, in any form: a government-contract record that grows or stalls, a priced secondary, the fate of the Meta services contract if Superintelligence Labs builds its own data operation, and the agent-evaluation market's size as it either materializes or dissolves into benchmark publishing. The record through early 2026 supports 'survived, repositioned, unproven at the new valuation' — and stops exactly there.
Scale after the deal is a case study in stake-sale arithmetic: the founder monetized his track record, the investor bought a team and a hedge, and the company itself traded neutrality for a sovereign-defense thesis. Whether that trade was fair is a question only future disclosures can price.
For more context, read Palantir: The AI Software Growth Record, Documented.
For more context, read anduril valuation.
For more context, read mistral ai review.